Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date

• Published in: Clinical, cosmetic and investigational dermatology Vol. 12; pp. 249 - 253
• Main Authors: Kivelevitch, Dario, Amin, Sima, Menter, Alan
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.04.2019; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Adalimumab; Antibodies; Apremilast; Dermatologic agents; Guselkumab; Interleukins; Ixekizumab; Monoclonal antibodies; Psoriasis; Review; scalp; Secukinumab; therapy; Ustekinumab; psoriasis; scalp; therapy; secukinumab

Psoriasis is an immune-mediated inflammatory dermatosis commonly affecting the scalp and fringes of the face, neck and ears. It may be difficult to treat and the presence of extensive and highly visible lesions may significantly influence psychosocial well-being. Secukinumab, a monoclonal antibody t...